However, considering that INMT downregulation has been associated with adverse outcomes in certain cancers and neurodegenerative conditions, future studies are warranted to explore whether enhancing INMT activity, either through SAM supplementation or novel small-molecule activators, may offer therapeutic value. The gene discussed is INMT; the disease is cancer.